Jacobs Levy Equity Management’s Aquestive Therapeutics AQST Stock Holding History

Jacobs Levy Equity Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-63,577	Closed	-$166K	–	998
2022 Q1	$166K	Sell	63,577 -116,802	-65%	-$341K	﹤0.01%	971
2021 Q4	$702K	Buy	180,379 +75,445	+72%	+$379K	﹤0.01%	791
2021 Q3	$458K	Hold	104,934	–	–	﹤0.01%	872
2021 Q2	$417K	Sell	104,934 -33,448	-24%	-$134K	﹤0.01%	897
2021 Q1	$720K	Buy	+138,382	New	+$736K	0.01%	803
2020 Q3	–	Sell	-10,000	Closed	-$49K	–	1020
2020 Q2	$49K	Sell	10,000 -48,473	-83%	-$223K	﹤0.01%	1021
2020 Q1	$128K	Buy	58,473 +33,407	+133%	+$127K	﹤0.01%	941
2019 Q4	$146K	Sell	25,066 -89,145	-78%	-$464K	﹤0.01%	961
2019 Q3	$363K	Buy	114,211 +28,315	+33%	+$106K	﹤0.01%	758
2019 Q2	$361K	Buy	+85,896	New	+$440K	0.01%	790

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VAFP

Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management's AQST Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Aquestive Therapeutics (AQST) in Q2 2022, closing a stake of 63,577 shares — an estimated $166K sold.

Jacobs Levy Equity Management first reported a position in AQST in Q2 2019 and held it in 10 quarters. The position peaked at $720K in Q1 2021. 45 funds tracked by Wall St. Rank hold AQST as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Aquestive Therapeutics position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 63,577 Aquestive Therapeutics shares in Q2 2022, an estimated $166K.
Jacobs Levy Equity Management first reported a position in Aquestive Therapeutics in Q2 2019 and held it in 10 quarters.
Jacobs Levy Equity Management's Aquestive Therapeutics position peaked at $720K in Q1 2021.
45 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.